NET Cancer Day
May 31 2011
The U.S. Food and Drug Administration announced on May 20, 2011 approval of Pfizer’s Sutent (sunitinib) for advanced pancreatic neuroendocrine tumor cancer patients with tumors that cannot be removed by surgery or that have spread (metastasized) to other parts of the body.
Nearly 90 percent of patients with pancreatic NETs are initially diagnosed with locally advanced or metastatic disease. Pancreatic NETs are reported in two to four people per million annually worldwide.
Mace Rothenberg, MD, Senior Vice President of Clinical Development and Medical Affairs for the Pfizer Oncology Business Unit said, “This approval is good news for the physicians, patients and caregivers who have had limited treatment options for this rare and difficult-to-treat tumor.” Read more